HK1126488A1 - Fused compounds that inhibit vanilloid receptor subtype 1 (vr1) receptor - Google Patents

Fused compounds that inhibit vanilloid receptor subtype 1 (vr1) receptor

Info

Publication number
HK1126488A1
HK1126488A1 HK09105273.8A HK09105273A HK1126488A1 HK 1126488 A1 HK1126488 A1 HK 1126488A1 HK 09105273 A HK09105273 A HK 09105273A HK 1126488 A1 HK1126488 A1 HK 1126488A1
Authority
HK
Hong Kong
Prior art keywords
receptor
compounds
fused compounds
subtype
inhibit vanilloid
Prior art date
Application number
HK09105273.8A
Other languages
English (en)
Inventor
Arthur Gomtsyan
Erol K Bayburt
Chih-Hung Lee
John R Koenig
Robert Schmidt
Kirill Lukin
Gilles Chambournier
Margaret Hsu
Robert M Leanna
Russel D Cink
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33555102&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1126488(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US10/459,925 external-priority patent/US7015233B2/en
Priority claimed from US10/864,068 external-priority patent/US7375126B2/en
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of HK1126488A1 publication Critical patent/HK1126488A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/06—Anti-spasmodics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Materials For Photolithography (AREA)
HK09105273.8A 2003-06-12 2006-11-14 Fused compounds that inhibit vanilloid receptor subtype 1 (vr1) receptor HK1126488A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/459,925 US7015233B2 (en) 2003-06-12 2003-06-12 Fused compounds that inhibit vanilloid subtype 1 (VR1) receptor
US10/864,068 US7375126B2 (en) 2003-06-12 2004-06-09 Fused compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
HK06112524.4A HK1093727A1 (en) 2003-06-12 2006-11-14 Fused compounds that inhibit vanilloid receptor subtype 1 (vr1) receptor

Publications (1)

Publication Number Publication Date
HK1126488A1 true HK1126488A1 (en) 2009-09-04

Family

ID=33555102

Family Applications (2)

Application Number Title Priority Date Filing Date
HK06112524.4A HK1093727A1 (en) 2003-06-12 2006-11-14 Fused compounds that inhibit vanilloid receptor subtype 1 (vr1) receptor
HK09105273.8A HK1126488A1 (en) 2003-06-12 2006-11-14 Fused compounds that inhibit vanilloid receptor subtype 1 (vr1) receptor

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HK06112524.4A HK1093727A1 (en) 2003-06-12 2006-11-14 Fused compounds that inhibit vanilloid receptor subtype 1 (vr1) receptor

Country Status (21)

Country Link
EP (2) EP2017265B1 (ru)
JP (2) JP4857113B2 (ru)
KR (2) KR101150324B1 (ru)
CN (1) CN102617464A (ru)
AT (2) ATE510824T1 (ru)
AU (2) AU2004247721C1 (ru)
BR (1) BRPI0411116A (ru)
CA (2) CA2526872C (ru)
CY (2) CY1108713T1 (ru)
DE (1) DE602004017329D1 (ru)
DK (2) DK2017265T3 (ru)
ES (1) ES2318308T3 (ru)
HK (2) HK1093727A1 (ru)
IL (4) IL172457A (ru)
MX (1) MXPA05013550A (ru)
NZ (3) NZ578264A (ru)
PL (2) PL2017265T3 (ru)
PT (2) PT2017265E (ru)
SI (2) SI2017265T1 (ru)
TW (3) TWI366461B (ru)
WO (1) WO2004111009A1 (ru)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4943837B2 (ja) 2003-04-03 2012-05-30 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 可溶性エポキシド加水分解酵素の改良インヒビター
US20090018092A1 (en) 2004-03-16 2009-01-15 The Regents Of The University Of California Reducing Nephropathy with Inhibitors of Soluble Epoxide Hydrolase and Epoxyeicosanoids
WO2006045119A2 (en) 2004-10-20 2006-04-27 The Regents Of The University Of California Improved inhibitors for the soluble epoxide hydrolase
JP2008523072A (ja) 2004-12-07 2008-07-03 ルーカス ファーマシューティカルズ， インコーポレイテッド タンパク質キナーゼの阻害剤
EP1828169A2 (en) 2004-12-07 2007-09-05 Locus Pharmaceuticals, Inc. Urea inhibitors of map kinases
AP2008004432A0 (en) 2005-10-07 2008-04-30 Glenmark Pharmaceuticals Sa Substituted benzofused derivatives and their use as vanilloid receptor ligands
US20070104780A1 (en) * 2005-10-25 2007-05-10 Lipari John M Formulation comprising a drug of low water solubility and method of use thereof
KR20080067361A (ko) * 2005-10-28 2008-07-18 아보트 러보러터리즈 Ｔｒｐｖ1 수용체를 억제하는 인다졸 유도체
AR059826A1 (es) 2006-03-13 2008-04-30 Univ California Inhibidores de urea conformacionalmente restringidos de epoxido hidrolasa soluble
RU2450006C2 (ru) * 2006-04-18 2012-05-10 Эбботт Лэборетриз Антагонисты ванилоидного рецептора подтипа 1(vr1) и их применение
WO2009081222A1 (en) 2007-12-21 2009-07-02 Glenmark Pharmaceuticals, S.A. Substituted tricyclic pyridine or pyrimidine vanilloid receptor ligands
KR101619341B1 (ko) 2008-01-28 2016-05-11 (주)아모레퍼시픽 바닐로이드 수용체 길항체로서의 신규 화합물, 이의 이성질체 또는 약제학적으로 허용가능한 염, 및 이를 함유하는 약학 조성물
US8691855B2 (en) 2008-07-02 2014-04-08 Amorepacific Corporation Compounds, isomer thereof, or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist and pharmaceutical compositions containing the same
CN102186836A (zh) * 2008-10-17 2011-09-14 雅培制药有限公司 Trpv1拮抗剂
WO2012054093A2 (en) 2010-01-29 2012-04-26 The Regents Of The University Of California Acyl piperidine inhibitors of soluble epoxide hydrolase
CN108329246B (zh) 2011-05-13 2021-02-26 阵列生物制药公司 作为trka激酶抑制剂的吡咯烷基脲和吡咯烷基硫脲化合物
WO2013167544A1 (en) * 2012-05-09 2013-11-14 Bayer Cropscience Ag 5-halogenopyrazole indanyl carboxamides
US9822118B2 (en) 2012-11-13 2017-11-21 Array Biopharma Inc. Bicyclic heteroaryl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
US9809578B2 (en) 2012-11-13 2017-11-07 Array Biopharma Inc. Pyrazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trkA kinase inhibitors
WO2014078325A1 (en) 2012-11-13 2014-05-22 Array Biopharma Inc. N-(monocyclic aryl),n'-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
US9828360B2 (en) 2012-11-13 2017-11-28 Array Biopharma Inc. Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
US9546156B2 (en) 2012-11-13 2017-01-17 Array Biopharma Inc. N-bicyclic aryl,N'-pyrazolyl urea, thiourea, guanidine cyanoguanidine compounds as TrkA kinase inhibitors
PL2920166T3 (pl) 2012-11-13 2017-05-31 Array Biopharma, Inc. Bicykliczne związki mocznika, tiomocznika, guanidyny i cyjanoguanidyny przydatne w leczeniu bólu
CN107857755B (zh) 2012-11-13 2020-10-27 阵列生物制药公司 作为trka激酶抑制剂的n-吡咯烷基、n′-吡唑基-脲、硫脲、胍和氰基胍化合物
WO2014078331A1 (en) 2012-11-13 2014-05-22 Array Biopharma Inc. N-(arylalkyl)-n'-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
US9981959B2 (en) 2012-11-13 2018-05-29 Array Biopharma Inc. Thiazolyl and oxazolyl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
WO2014078372A1 (en) 2012-11-13 2014-05-22 Array Biopharma Inc. Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
HUE045340T2 (hu) 2014-05-15 2019-12-30 Array Biopharma Inc 1-((3S,4R)-4-(3-fluorfenil)-1-(2-metoxietil)pirrolidin-3-il)-3-(4-metil-3-(2- metilpirimidin-5-il)-1-fenil-1H-pirazol-5-il)karbamid mint TrkA kináz inhibitor
DE102022104759A1 (de) 2022-02-28 2023-08-31 SCi Kontor GmbH Co-Kristall-Screening Verfahren, insbesondere zur Herstellung von Co-Kristallen

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW536734B (en) * 2000-07-31 2003-06-11 Clariant Int Ltd Process for manufacturing a microelectronic device
CA2455754A1 (en) * 2001-07-31 2003-02-20 Bayer Healthcare Ag Amine derivatives
JP2003192587A (ja) * 2001-12-26 2003-07-09 Bayer Ag 尿素誘導体
DE60325834D1 (de) * 2002-02-20 2009-03-05 Abbott Lab Kondensierte azabicyclischeverbindungen als inhibitoren des vanilloid-rezeptors 1 (vr1)
GB0206876D0 (en) 2002-03-22 2002-05-01 Merck Sharp & Dohme Therapeutic agents
EP1506166B1 (en) * 2002-05-17 2011-11-16 Janssen Pharmaceutica NV Aminotetralin-derived urea modulators of vanilloid vr1 receptor

Also Published As

Publication number Publication date
PT1658269E (pt) 2009-01-09
KR20110089464A (ko) 2011-08-08
TW200509926A (en) 2005-03-16
DK1658269T3 (da) 2009-01-12
EP2017265A1 (en) 2009-01-21
BRPI0411116A (pt) 2006-07-18
AU2010257277A1 (en) 2011-01-13
NZ590234A (en) 2012-07-27
SI2017265T1 (sl) 2011-09-30
ES2318308T3 (es) 2009-05-01
PL1658269T3 (pl) 2009-08-31
DE602004017329D1 (de) 2008-12-04
IL172457A0 (en) 2006-04-10
ATE510824T1 (de) 2011-06-15
CY1108713T1 (el) 2014-04-09
EP2017265B1 (en) 2011-05-25
DK2017265T3 (da) 2011-09-19
CY1111945T1 (el) 2015-11-04
IL172457A (en) 2011-12-29
ATE411982T1 (de) 2008-11-15
NZ578264A (en) 2011-02-25
WO2004111009A1 (en) 2004-12-23
KR101150324B1 (ko) 2012-06-13
AU2004247721C1 (en) 2011-12-22
TW201038269A (en) 2010-11-01
AU2010257277B2 (en) 2011-08-18
IL207335A (en) 2012-02-29
MXPA05013550A (es) 2006-04-05
NZ543713A (en) 2009-08-28
EP1658269B1 (en) 2008-10-22
PL2017265T3 (pl) 2011-11-30
PT2017265E (pt) 2011-07-29
IL215997A0 (en) 2011-12-29
KR20060058769A (ko) 2006-05-30
JP2011153148A (ja) 2011-08-11
JP4857113B2 (ja) 2012-01-18
AU2004247721A1 (en) 2004-12-23
AU2004247721B2 (en) 2011-01-20
CN102617464A (zh) 2012-08-01
HK1093727A1 (en) 2007-03-09
TW201300361A (zh) 2013-01-01
TWI394569B (zh) 2013-05-01
EP1658269A1 (en) 2006-05-24
JP2007500753A (ja) 2007-01-18
SI1658269T1 (sl) 2009-04-30
IL216046A0 (en) 2011-12-29
KR101138216B1 (ko) 2012-09-05
TWI366461B (en) 2012-06-21
CA2756058A1 (en) 2004-12-23
IL207335A0 (en) 2010-12-30
CA2526872C (en) 2013-02-05
CA2526872A1 (en) 2004-12-23

Similar Documents

Publication Publication Date Title
IL207335A0 (en) Fused compounds that inhibit vanilloid receptor subtype 1 (vr1) receptor
IL173269A0 (en) Compounds for inflammation and immune-related uses
AU2003259747A8 (en) Substituted hihydroquinolines as glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
TW200621232A (en) Compounds for inflammation and immune-related uses
HK1056732A1 (en) 1,5 Benzothiazepines and their use as antihyperlipidemics
MY128063A (en) Aromatic heterocyclic compound as antiinflammatory agents
WO2006062981A3 (en) Antagonists to the vanilloid receptor subtype 1 (vr1) and uses thereof
WO2003014064A8 (en) Naphthylurea and naphthylacetamide derivatives as vanilloid receptor 1 (vr1) antagonists
IS6275A (is) Heteróhringa efnasambönd og notkun þeirra sem mótlyf efnaskiptaglútamatviðtaka
HRP20110105T1 (en) Heterocyclic inhibitors of mek
CA2369504A1 (en) Pyrazole compositions useful as inhibitors of erk
AU2003202216A1 (en) Glucocorticoid mimetics, methods of making them, pharmaceutical formulations containing them and uses thereof
WO2002074758A3 (en) Novel amines as histamine-3 receptor ligands and their therapeutic applications
AU2002321910A1 (en) Pyrazole-derived kinase inhibitors and uses thereof
MX2007007100A (es) Benzisotiazol-1,1-dioxido que actua como antagonistas para el subtipo 1 del receptor de vanilloida (vr1) y usos de los mismos.
MXPA04006031A (es) Compuestos para el tratamiento de trastornos inflamatorios.
WO2005040121A3 (en) Amides that inhibit vanilloid receptor subtype 1 (vr1) receptor
MXPA04005988A (es) 3,4-dihidro-1h-isoquinolin-2-il-derivados.

Legal Events

Date Code Title Description
CORR Corrigendum

Free format text: CORRECTED DATA OF SECTION 20 TO JOURNAL OF : [72] GOMTSYAN, ARTHUR - BAYBURT, EROL, K. - LEE, CHIH-HUNG - KOENIG, JOHN, R. - SCHMIDT, ROBERT - LUKIN, KIRILL - CHAMBOURNIER, GILLES - HSU, MARGARET - LEANNA, ROBERT, M. - CINK, RUSSEL, D. - THE FOLLOWING ITEMS IN BOLD SHOW THE CORRECTED DATA OF THE NOTICE OF GRANTED - DATED 2.10.2009

PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20150610